Freedom Biosciences Announces FDA Approval of IND Application for FREE001 in Patients with Treatment-Resistant Depression

/PRNewswire/ -- Freedom Biosciences, Inc. ("Freedom Bio" or the "Company"), a clinical-stage biotechnology platform focused on developing next-generation...

Related Keywords

United States ,Jannsen Spravato ,Dina Burkitbayeva ,David Hough ,Smith Carls ,John Krystal ,Rob Berman ,Ius Dept Of Health ,Biohaven Pharmaceuticals ,National Survey On Drug ,Mental Health Services Administration ,Freedom Biosciences Inc ,Mental Health Indicators ,Drug Administration ,Human Services ,National Burden Of Treatment ,Psychiatry At Yale University ,A Paradigm Shift For Depression Research ,Freedom Bio ,Chief Scientific Advisor ,Yale University ,Psymed Ventures ,Chief Medical Officer ,Senior Medical Advisor ,Scientific Advisory Board ,Paradigm Shift ,Depression Research ,Dose Frequency Study ,Intravenous Ketamine ,Patients With Treatment Resistant ,Mental Health Services ,Key Substance Use ,Drug Use ,National Burden ,Treatment Resistant Depression ,Major Depressive Disorder ,Freedom Biosciences ,